PRIUM’S Michael Gavin Discusses Urine Drug Monitoring in Workers’ Compensation at the National Rx Drug Abuse Summit

Workers’ compensation payers and providers need clear drug monitoring strategies to ensure patient safety

ATLANTA--()--PRIUM’s President Michael Gavin will participate in a panel on urine drug monitoring in workers’ compensation at the National Rx Drug Abuse Summit.

Moderated by Daniel Blaney-Koen, JD, an attorney with the American Medical Association Advocacy Resource Center, the April 7 session examines the clinical rationale for urine drug monitoring, explains why appropriate monitoring does not always occur and discusses financial incentives for over-testing. “Best practices call for guidelines-driven, patient-centered care and proactive patient identification,” said Gavin. “Particularly in light of the opioid epidemic, payers and providers need to develop clear drug monitoring strategies to ensure patient safety.”

Joining Gavin on the panel is Jo-Ellen Abou Nader, senior director with Express Scripts, and Elaine Jeter, MD, medical director for Palmetto GBA, which administers Medicare health insurance for the Centers for Medicare & Medicaid Services. Panelists also discuss how pharmacy benefit managers work with payers to use UDM to detect fraud and waste and examine states’ UDM utilization review regulations.

“Rules for the provision of drug monitoring and options available to providers and payers vary widely by state,” said Gavin. “A clear understanding of the regulatory environment is critical to ensuring drug monitoring is a useful tool to ensure patient safety.”

The 4th Annual National Rx Drug Abuse Summit takes place April 6-9, 2015 at The Westin Peachtree Plaza in Atlanta. The largest national collaboration of professionals seeking to address Rx drug abuse, misuse and diversion, the Summit unites stakeholders from government agencies, education, and healthcare fields.

About PRIUM

An Ameritox solutions provider, PRIUM sets the industry standard for workers’ compensation medical interventions through its ability to secure higher agreement rates and to help ensure compliance with modified treatment plans. The hallmark of the medical intervention company’s success is a collaborative physician engagement process encompassing evidence-based medicine, clinical oversight, and jurisdictional guidelines to facilitate optimal financial and clinical outcomes. PRIUM helps eliminate unnecessary treatment through a comprehensive approach that includes complex medical interventions, utilization reviews, urine drug monitoring, and independent medical exams. PRIUM can be at 888.588.4964.

Website: www.prium.com

Blog: www.priumevidencebased.com

Twitter: @PRIUM1

Contacts

For PRIUM
Helen Knight, 813-690-4787
helen@kingknight.com

Release Summary

PRIUM's President Michael Gavin discusses urine drug monitoring at the National Rx Drug Abuse Summit.

Contacts

For PRIUM
Helen Knight, 813-690-4787
helen@kingknight.com